By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Audentes Therapeutics 

101 Montgomery Street
Suite 2650
San Francisco  California  94104  U.S.A.
Phone: 415-638-6556 Fax: n/a


Audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare diseases through the application of gene therapy technology.

The company consists of a focused, experienced, and passionate team driven by the goal of improving the lives of patients. We take pride in strong, global relationships with the patient, research, and medical communities.

Key Statistics

Ownership: Public

Web Site: Audentes
Employees: n/a
Symbol: BOLD


Company News
Audentes (BOLD) Announces Dosing Of First Patient In ASPIRO, A Phase I/II Clinical Trial Of AT132 For The Treatment Of X-Linked Myotubular Myopathy 9/21/2017 6:47:11 AM
Audentes (BOLD) Reports Second Quarter 2017 Financial Results And Provides Corporate Update 8/10/2017 1:45:55 PM
Audentes (BOLD) Announces Appointment Of Fulvio Mavilio, Ph.D. To Vice President Scientific Affairs, Europe 7/18/2017 9:03:02 AM
Audentes (BOLD) Appoints Jennifer Jarrett To Board Of Directors 6/13/2017 8:27:01 AM
Audentes (BOLD) Reports First Quarter 2017 Financial Results And Provides Corporate Update 5/11/2017 11:07:09 AM
Audentes (BOLD) Announces Appointment Of John T. Gray, Ph.D. To Senior Vice President And Chief Scientific Officer 5/8/2017 7:37:03 AM
Audentes (BOLD) Announces Pricing Of Public Offering Of Common Stock 4/19/2017 7:06:20 AM
Audentes (BOLD) Announces Proposed Public Offering Of Common Stock 4/18/2017 7:41:06 AM
Audentes (BOLD) Announces FDA Clearance Of Investigational New Drug Application For AT132 To Treat X-Linked Myotubular Myopathy 4/3/2017 8:47:39 AM
Audentes (BOLD) Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update 3/9/2017 11:22:37 AM